Mail

ALKS - Alkermes plc

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

32.44

-0.61 (-1.85%)

At close: 4:00PM EST

Stock chart is not supported by your current browser

Previous Close	33.05
Open	33.11
Bid	0.00 x 800
Ask	0.00 x 800
Day's Range	32.03 - 33.39
52 Week Range	27.54 - 71.22
Volume	487,101
Avg. Volume	993,663

Market Cap	5.041B
Beta (3Y Monthly)	2.11
PE Ratio (TTM)	N/A
EPS (TTM)	-0.90
Earnings Date	Feb 12, 2019 - Feb 18, 2019
Forward Dividend & Yield	N/A (N/A)
Ex-Dividend Date	N/A
1y Target Est	42.69

Trade prices are not sourced from all markets

All

News

Press Releases

ACCESSWIRE11 hours ago
LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 Investing In Alkermes plc To Contact The Firm
NEW YORK, NY / ACCESSWIRE / January 23, 2019 / Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Alkermes plc ("Alkermes" or the "Company")(ALKS) of the February 25, 2019 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. If you invested in Alkermes stock or options between February 17, 2017 and November 1, 2018 and would like to discuss your legal rights, click here: www.faruqilaw.com/ALKS.
GlobeNewswire14 hours ago
CLASS ACTION UPDATE for WBT, TS and ALKS: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court and further details about the cases can be found at the links provided.
GlobeNewswire15 hours ago
INVESTOR ACTION NOTICE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Alkermes plc and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Alkermes plc (“Alkermes” or “the Company”) (NASDAQ: ALKS) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. You can also reach us through the firm's website at www.schallfirm.com, or by email at brian@schallfirm.com.
GlobeNewswire16 hours ago
SHAREHOLDER ALERT: PPDF CMCM DXC ALKS: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines
NEW YORK, Jan. 23, 2019 -- The Law Offices of Vincent Wong announce that class actions have commenced on behalf of shareholders of the following companies. If you suffered a.
GlobeNewswire2 days ago
The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of NVDA, AGN, DXC and ALKS
NEW YORK, Jan. 22, 2019 -- The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. If you suffered a.
ACCESSWIRE2 days ago
INVESTOR ACTION NOTICE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Alkermes plc and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / January 22, 2019 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Alkermes plc ("Alkermes" or "the Company") (NASDAQ: ALKS) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. The FDA issued a briefing document about Alkermes' new drug application for ALKS 5461 on October 30, 2018, in advance of an FDA advisory committee meeting about the drug.
ACCESSWIRE2 days ago
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Alkermes plc - ALKS
NEW YORK, NY / ACCESSWIRE / January 22, 2019 / Pomerantz LLP is investigating claims on behalf of investors of Alkermes plc ("Alkermes" or the "Company") (ALKS). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. The investigation concerns whether Alkermes and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
ACCESSWIRE2 days ago
SHAREHOLDER ALERT -- Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Alkermes plc, Inc. (ALKS) and Lead Plaintiff Deadline - February 25, 2019
NEW YORK, NY / ACCESSWIRE / January 22, 2019 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed Alkermes plc, Inc.("Alkermes" or the "Company") (NASDAQ: ALKS) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired Alkermes securities between February 17, 2017 and November 1, 2018, inclusive (the "Class Period"). This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934.
Simply Wall St.2 days ago
Calculating The Fair Value Of Alkermes plc (NASDAQ:ALKS)
Does the January share price for Alkermes plc (NASDAQ:ALKS) reflect it's really worth? Today, I will calculate the stock's intrinsic value by taking the expected future cash flows and discounting Read More...
ACCESSWIRE3 days ago
SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Alkermes plc and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / January 21, 2019 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Alkermes plc ("Alkermes" or "the Company") (NASDAQ: ALKS) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. The FDA issued a briefing document about Alkermes' new drug application for ALKS 5461 on October 30, 2018, in advance of an FDA advisory committee meeting about the drug.
GlobeNewswire3 days ago
SHAREHOLDER ALERT -- Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Alkermes plc, Inc. (ALKS) and Lead Plaintiff Deadline: February 25, 2019
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed Alkermes plc, Inc. ("Alkermes" or the "Company") (NASDAQ: ALKS) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired Alkermes securities between February 17, 2017 and November 1, 2018, inclusive (the “Class Period”). Such investors are encouraged to join this case by visiting the firm’s site: bgandg.com/alks. This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934.
GlobeNewswire3 days ago
ALKS DEADLINE: Rosen Law Firm Reminds Alkermes Public Limited Company Investors of Important February 25 Deadline in First-Filed Securities Class Action Lawsuit – ALKS
NEW YORK, Jan. 21, 2019 -- Rosen Law Firm, a global investor rights law firm, announces it has filed a class action lawsuit on behalf of purchasers of the securities of.
GlobeNewswire5 days ago
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Alkermes plc – ALKS
Pomerantz LLP is investigating claims on behalf of investors of Alkermes plc (“Alkermes” or the “Company”) (NASDAQ: ALKS). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. On October 30, 2018, the U.S. Food and Drug Administration (“FDA”) released a briefing document concerning the Company’s New Drug Application (“NDA”) for ALKS 5461 ahead of an FDA advisory committee meeting for the drug.
ACCESSWIRE6 days ago
SHAREHOLDER ALERT: Pawar Law Group Announces a Securities Class Action Lawsuit Against Alkermes Public Limited Company - ALKS
NEW YORK, NY / ACCESSWIRE / January 18, 2019 / Pawar Law Group announces that a class action lawsuit has been filed on behalf of shareholders who purchased shares of Alkermes Public Limited Company (NASDAQ: ...
ACCESSWIRE6 days ago
SHAREHOLDER ALERT -- Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Alkermes plc, Inc. (ALKS) and Lead Plaintiff Deadline: February 25, 2019
NEW YORK, NY / ACCESSWIRE / January 18, 2019 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed Alkermes plc, Inc.("Alkermes" or the "Company") (NASDAQ: ALKS) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired Alkermes securities between February 17, 2017 and November 1, 2018, inclusive (the "Class Period"). This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934.
GlobeNewswire6 days ago
INVESTOR ACTION REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Alkermes plc and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Alkermes plc (“Alkermes” or “the Company”) (NASDAQ: ALKS) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. You can also reach us through the firm's website at www.schallfirm.com, or by email at brian@schallfirm.com.
ACCESSWIRE7 days ago
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Alkermes plc – ALKS
NEW YORK, NY / ACCESSWIRE / January 16, 2019 / Pomerantz LLP is investigating claims on behalf of investors of Alkermes plc (''Alkermes'' or the ''Company'') (ALKS). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. The investigation concerns whether Alkermes and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
ACCESSWIRE8 days ago
IMPORTANT DEADLINE ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Alkermes plc and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / January 16, 2019 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Alkermes plc ("Alkermes" or "the Company") (NASDAQ: ALKS) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. The FDA issued a briefing document about Alkermes' new drug application for ALKS 5461 on October 30, 2018, in advance of an FDA advisory committee meeting about the drug.
ACCESSWIRE8 days ago
SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Alkermes plc, Inc. (ALKS) and Lead Plaintiff Deadline: February 25, 2019
NEW YORK, NY / ACCESSWIRE / January 16, 2019 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed Alkermes plc, Inc.("Alkermes" or the "Company") (NASDAQ: ALKS) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired Alkermes securities between February 17, 2017 and November 1, 2018, inclusive (the "Class Period"). This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934.
PR Newswire8 days ago
Alkermes Announces Recipients of 1st Annual ALKERMES PATHWAYS RESEARCH AWARDS (SM) Program
DUBLIN, Jan. 16, 2019 /PRNewswire/ -- Alkermes plc (ALKS) today announced the recipients of the ALKERMES PATHWAYS RESEARCH AWARDSSM program, designed to support the next generation of researchers working on the front lines to advance understanding and awareness of central nervous system (CNS) disorders. In its inaugural year, the Pathways program will provide an aggregate of $400,000 in grants to junior investigators who have demonstrated their commitment to helping those living with substance use disorders (SUD), including those associated with the use of opioids and alcohol. "An estimated one-in-seven people in the U.S. will develop a substance use disorder in their lifetime1, which is why we urgently need to accelerate research efforts focused on improving prevention, treatment and awareness of this public health crisis," said Craig Hopkinson, M.D., Chief Medical Officer and Senior Vice President of Medicines Development and Medical Affairs at Alkermes.
GlobeNewswire8 days ago
ALKS ALERT: Rosen Law Firm Files First Securities Class Action Lawsuit Against Alkermes Public Limited Company; Reminds Investors with $100K in Losses of Important Deadline – ALKS
NEW YORK, Jan. 15, 2019 -- Rosen Law Firm, a global investor rights law firm, announces it has filed a class action lawsuit on behalf of purchasers of the securities of.
GlobeNewswire9 days ago
CLASS ACTION UPDATE for DXC and ALKS: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
NEW YORK, Jan. 15, 2019 -- Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies..
ACCESSWIRE9 days ago
INVESTOR ACTION ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Alkermes plc and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / January 14, 2019 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Alkermes plc ("Alkermes" or "the Company") (NASDAQ: ALKS) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. The FDA issued a briefing document about Alkermes' new drug application for ALKS 5461 on October 30, 2018, in advance of an FDA advisory committee meeting about the drug.
GlobeNewswire9 days ago
SHAREHOLDER ALERT: DNKEY ATUS DXC ALKS: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines
NEW YORK, Jan. 14, 2019 -- The Law Offices of Vincent Wong announce that class actions have commenced on behalf of shareholders of the following companies. If you suffered a.
GlobeNewswire9 days ago
LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 Investing In Alkermes plc To Contact The Firm
Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Alkermes plc ("Alkermes" or the "Company")(ALKS) of the February 25, 2019 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. If you invested in Alkermes stock or options between February 17, 2017 and November 1, 2018 and would like to discuss your legal rights, click here: www.faruqilaw.com/ALKS.